TY  - JOUR
AU  - Regnery, Sebastian
AU  - Adeberg, Sebastian
AU  - Dreher, Constantin
AU  - Oberhollenzer, Johanna
AU  - Meissner, Jan-Eric
AU  - Goerke, Steffen
AU  - Windschuh, Johannes
AU  - Deike-Hofmann, Katerina
AU  - Bickelhaupt, Sebastian
AU  - Zaiss, Moritz
AU  - Radbruch, Alexander
AU  - Bendszus, Martin
AU  - Wick, Wolfgang
AU  - Unterberg, Andreas
AU  - Rieken, Stefan
AU  - Debus, Jürgen
AU  - Bachert, Peter
AU  - Ladd, Mark
AU  - Schlemmer, Heinz-Peter
AU  - Paech, Daniel
TI  - Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients.
JO  - OncoTarget
VL  - 9
IS  - 47
SN  - 1949-2553
CY  - [S.l.]
PB  - Impact Journals LLC
M1  - DKFZ-2019-00743
SP  - 28772-28783
PY  - 2018
AB  - To prospectively investigate chemical exchange saturation transfer (CEST) MRI in glioblastoma patients as predictor of early tumor progression after first-line treatment.Twenty previously untreated glioblastoma patients underwent CEST MRI employing a 7T whole-body scanner. Nuclear Overhauser effect (NOE) as well as amide proton transfer (APT) CEST signals were isolated using Lorentzian difference (LD) analysis and relaxation compensated by the apparent exchange-dependent relaxation rate (AREX) evaluation. Additionally, NOE-weighted asymmetric magnetic transfer ratio (MTRasym) and downfield-NOE-suppressed APT (dns-APT) were calculated. Patient response to consecutive treatment was determined according to the RANO criteria. Mean signal intensities of each contrast in the whole tumor area were compared between early-progressive and stable disease.Pre-treatment tumor signal intensity differed significantly regarding responsiveness to first-line therapy in NOE-LD (p = 0.0001), NOE-weighted MTRasym (p = 0.0186) and dns-APT (p = 0.0328) contrasts. Hence, significant prediction of early progression was possible employing NOE-LD (AUC = 0.98, p = 0.0005), NOE-weighted MTRasym (AUC = 0.83, p = 0.0166) and dns-APT (AUC = 0.80, p = 0.0318). The NOE-LD provided the highest sensitivity (91
LB  - PUB:(DE-HGF)16
C6  - pmid:29983895
C2  - pmc:PMC6033360
DO  - DOI:10.18632/oncotarget.25594
UR  - https://inrepo02.dkfz.de/record/143134
ER  -